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Objectives: Platelet-derived endothelial cell growth factor (PD-ECGF) is identical to thymidine phosphorylase (TP), and
it can induce angiogenesis, including arteriogenesis, in chronically ischemic canine myocardium. Because its effect on
peripheral arterial disease has not been elucidated, we investigated whether overexpression of PD-ECGF/TP could
ameliorate chronic limb ischemia in rabbits.
Methods: Left femoral arteries were resected from 24 male rabbits. After 10 days, a plasmid vector containing human
PD-ECGF/TP complimentary DNA was injected into 10 sites in the adductor muscles. Control groups received either
the LacZ plasmid vector or saline vehicle only (n 8 per group). Blood pressure was measured in the calf before surgery,
at the onset of ischemia, 10 days later, and 20 and 30 days after gene transfer. Collateral vessel development and limb
perfusion were assessed by angiography, and resected tissues underwent molecular and histologic examination.
Results: In the PD-ECGF/TP group, human PD-ECGF/TP messenger RNA and protein were still detected at 30 days
after treatment. Calf blood pressure decreased significantly after femoral artery resection in all three groups. It
subsequently showed a greater increase in the PD-ECGF/TP group than in either control group, and the difference was
significant at 20 days after treatment (PD-ECGF/TP, 97.4  7.4; LacZ, 58.6  6.9; saline, 41.3  3.6). Immunohis-
tochemical staining demonstrated an increased ratio of capillaries and arterioles to muscle fibers in the PD-ECGF/TP
group (2.14  0.13 and 1.51  0.06), but not in the LacZ group (1.39  0.04 and 0.71  0.05) or the saline group
(1.34  0.05 and 0.71  0.04, P < .01). The angiographic score was higher in the PD-ECGF/TP group (0.96  0.08)
than in the LacZ group (0.50  0.02) or saline group (0.51  0.03) at 30 days after gene transfer (P < .01).
Conclusions: This study demonstrated that PD-ECGF/TP gene transfer induced angiogenesis and decreased ischemia in
a rabbit hindlimb model by promoting arteriogenesis, suggesting that targeting this gene may be a promising therapeutic
strategy for peripheral vascular disease. ( J Vasc Surg 2006;44:1322-8.)
Clinical Relevance: Lower extremity peripheral arterial disease (PAD) due to atherosclerotic vascular disease is a major
health problem in the world. Surgical or percutaneous revascularization strategies may improve blood flow in selected
patients with PAD; however, a large number of patients with PAD are not suitable for revascularization. A variety of
strategies have been attempted for the effective development of collateral vessels, and the most widely studied procedures
are local delivery of angiogenic growth factors, such as vascular endothelial growth factor, basic fibroblast growth factor,
or bone marrow cells. In our previous studies, we have demonstrated the therapeutic effects of platelet-derived
endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in ischemic myocardium; however, the effect of
PD-ECGF/TP on PAD has not been elucidated. The purpose of this study was to evaluate the effect of PD-ECGF/TP
on a rabbit hindlimb ischemic model. We found that PD-ECGF/TP gene transfer into the ischemic area significantly
induced angiogenesis and arteriogenesis after a functional improvement in collateral blood flow in a rabbit extremity
ischemic limb model. This could lead to a new therapeutic strategy for treating PAD in the clinic.Atherosclerotic peripheral arterial disease (PAD) of the
lower extremity is a major health problem worldwide.1
Although surgical or percutaneous revascularization may
improve blood flow in selected patients with PAD, many
patients are not candidates for such revascularization pro-
cedures. A variety of other strategies have also been tried for
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1322the creation of collateral vessels, with the most widely
studied technique being local delivery of angiogenic
growth factors such as vascular endothelial growth factor
(VEGF)2 or fibroblast growth factor (FGF). 3 Recent investi-
gations have confirmed that exogenous angiogenic growth
factors can induce the formation of new blood vessels and
increase collateral blood flow in ischemic tissues. 2
A variety of physiologic growth factors can potentially
induce or accelerate angiogenesis by stimulating endothe-
lial cell proliferation andmigration. Among these, the most
potent endothelial mitogen may be VEGF. 4 Previous
in vivo studies have suggested that VEGF not only increases
the formation of collateral vessels but also modifies the
vasomotor response of collaterals. Bauters et al5 demon-
strated angiographically that VEGF administration could
improve the endothelium-dependent responses of rela-
tively large collateral vessels.
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tions of these angiogenic cytokines have been identified by
Epstein et al.6,7 For example, VEGF causes edema and
induces the development of functionally abnormal blood
vessels, and VEGF and FGF can both trigger the growth of
neoplasms or increase atherosclerotic plaque size and insta-
bility, in addition to causing other problems. The side
effects of these growth factors thus limit their therapeutic
usefulness and have prompted a search for other angiogenic
factors without such complications.
Platelet-derived endothelial cell growth factor (PD-
ECGF) is identical to thymidine phosphorylase (TP). Al-
though the receptor or signal pathway related to PD-
ECGF/TP has not yet been identified, this enzyme
catalyzes the reversible dephosphorylation of thymidine to
thymine and 2-deoxy-D-ribose-1-phosphate, a process that
helps to maintain the nucleotide pool.8 Sengupta et al9
have reported that equimolar concentrations of PD-
ECGF/TP and VEGF induce similar in vitro recovery of
wounded endothelial monolayers, suggesting that PD-
ECGF/TP might also have an angiogenic effect in vivo
similar to that of VEGF. Indeed, PD-ECGF/TP has al-
ready been demonstrated to possess angiogenic activity
in vivo, showing chemotaxis for endothelial cells and con-
ferring resistance to apoptosis induced by hypoxia.9-12
These characteristics of PD-ECGF/TP strongly sug-
gest that it could be useful for gene therapy designed to
promote angiogenesis and inhibit apoptosis in settings such
as myocardial ischemia. We have shown in previous studies
that plasmid vector-mediated transfer of the PD-ECGF/
TP gene stimulated angiogenesis and arteriogenesis in ex-
perimental myocardial ischemia, inhibited cardiac myocyte
apoptosis, decreased the extent of myocardial infarction,
enhanced myocardial blood flow, and improved cardiac
function.13 The effect of PD-ECGF/TP gene transfer on
PADhas not, to our knowledge, been examined previously.
Accordingly, the present study was performed to evaluate
the response to PD-ECGF/TP gene transfer in a rabbit
hindlimb ischemia model.
MATERIALS AND METHODS
Plasmid DNA. Plasmid vectors encoding the full-
length human PD-ECGF/TP or LacZ complementary
DNA (cDNA) were constructed as described previously.13
Purified plasmid DNA for these experiments was prepared
from TOP 10F= Escherichia coli (Invitrogen Corp, Carls-
bad, Calif) using an endotoxin-free plasmid extraction kit
(Qiagen GmbH, Hilden, Germany).
Rabbit hindlimb ischemia model. Twenty-four male
New Zealand White rabbits weighing 2.2 to 2.4 kg (Japan
SLC, Shizuoka, Japan) were randomized to a PD-ECGF/TP
group, a LacZ group, and a saline group (n  8 per group).
The rabbits were anesthetized with a mixture of xylazine
(5 mg/kg) and ketamine (50 mg/kg) before hindlimb
ischemia was created as described previously.14
In brief, a longitudinal incision was made in the left
hindlimb, extending inferiorly from the inguinal ligament
to a point just proximal to the patella. The left femoralartery was dissected free from the surrounding tissues, and
the femoral vein along its entire length, and all the branches
of the femoral artery (including the inferior epigastric, deep
femoral, lateral circumflex, and superficial epigastric arter-
ies) were also dissected. After dissection of the popliteal and
saphenous arteries distally, the external iliac artery and all of
the above arteries were ligated with 4-0 silk. Finally, the left
femoral artery was completely resected from its origin at the
external iliac artery to the point where it bifurcates to form
the saphenous and popliteal arteries. The femoral vein was
left in situ. Excision of the femoral artery resulted in retro-
grade thrombosis and occlusion of the external iliac artery.
The incision was closed, and the rabbits were allowed
to recover. All rabbits received subcutaneous cefazolin so-
dium hydrate (1.0 mg/kg per day) for 3 days after surgery.
In the PD-ECGF/TP group, at 10 days after the
creation of hindlimb ischemia, a total dose of 5 mg of
PD-ECGF/TP plasmid diluted in 2 mL of saline was
injected at 10 different sites into the adductor muscles (0.2
mL/site) through a 27-gauge needle, based on a grid sheet
that was devised in a pilot study. Similarly, the LacZ group
received 5 mg of LacZ plasmid vector, and the saline group
received of 2 mL of saline only.
At 30 days after these treatments, the rabbits were
killed by an intravenous overdose of pentobarbital. Tissue
blocks were obtained from the adductor muscles, fixed in
4% formalin, and embedded in paraffin. Other tissue sam-
ples for molecular studies and endothelial lectin staining
were snap-frozen in liquid nitrogen and stored at –80 °C
until use.
Handling of the animals was in compliance with the
Guidelines of the Institutional Animal Care and Use Com-
mittee (Faculty of Medical Sciences, University of Fukui,
Japan) and conformed to the Guide for the Care and Use of
Laboratory Animals (US National Institutes of Health
Publication No. 85-23, revised in 1996).
Calf blood pressure. We measured the calf blood
pressure using a neonatal vital sign monitor (Automatic
Sphygmomanometer, BSM-2310; Nihon Kohden, Tokyo,
Japan). In brief, both hindlimbs were shaved and cleaned
on the day before measurement. After anesthesia, a 3-cm-
wide neonatal cuff was wrapped around the calf along the
course of the posterior tibial artery to determine the sys-
tolic, diastolic, and mean blood pressures. These values
were obtained at four times: immediately before surgery,
10 days after femoral artery resection, and at 20 and 30 days
after gene transfer. Blood pressure data were used to calcu-
late the calf blood pressure ratio, defined as the ratio of
systolic pressure in the ischemic left hindlimb to that in the
normal right hindlimb.2
Angiography. Angiography was performed as de-
scribed previously.15 In brief, the right common carotid
artery was exposed through a ventral incision under anes-
thesia. A 10-cm-long 4F introducer sheath (Terumo,
Tokyo, Japan) was introduced into the exposed artery by
using the Seldinger technique. A 0.38-mm guidewire and
catheter were advanced to a point 1 cm proximal to the
bifurcation of the common iliac artery.15,16 Immediately
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Tanabe, Osaka, Japan) was infused at a rate of 60 mL/min.
Perfusion of the hindlimbwas observed on amonitor in real
time, and an angiographic image was obtained exactly
4 seconds after the start of contrast infusion.
A grid of lines spaced 2.5 mm apart was placed over the
angiogram in the region of the medial thigh. The number
of opacified arteries crossing each line segment and the total
number of line segments in the grid that covered themedial
thigh area were counted in a blinded fashion. The angio-
graphic score was calculated as the number of lines overly-
ing opacified arteries divided by the total number of lines in
the ischemic thigh region.2,17 Accordingly, this score re-
flected the vessel density in the medial thigh.
Analysis of PD-ECGF/TP expression. Total RNA
was isolated from the adductor muscles of each rabbit.
Then 1 g of RNA was treated with DNase (Sigma; St.
Louis, Mo) and used for first-strand cDNA synthesis with a
kit, as described previously (1st Strand cDNA Synthesis;
Roche Diagnostics, Basel, Switzerland).18 A pair of primers
(forward: 5=-AGAGCCCAGAGCAGATGCAAGT-3=; re-
verse: 5=-CAGCCCCTCCACGAGTTTCTTA-3=) bind-
ing to conserved regions of human PD-ECGF/TP cDNA
was employed to generate a 181-bp product, a second set of
primers (forward: 5=-GAGATCGTGCGGGACATCAA-3=;
reverse: 5=-CAGGAAGGAGGGCTGGAACA-3=) binding
to conserved regions of rabbit -actin cDNA was used to
generate a 185-bp product. For polymerase chain reaction
(PCR) amplification, an Advantage II PCR Kit (Clontech,
Mountain View, Calif ) was used for 45 cycles for human
PD-ECGF/TP and 35 cycles for rabbit -actin.
Western blotting to quantify PD-ECGF/TP protein
expression and X-gal staining to assess LacZ gene expres-
sion were done as described previously.13
Histologic examination. Serial sections (4 to 5 m
thick) were cut and routine staining with hematoxylin and
eosin was performed. Immunostaining using a mouse anti-
human PD-ECGF/TP primary antibody (645-1; a gift
from Chugai Pharmaceutical, Tokyo, Japan) was per-
formed to detect expression at the vector injection sites.
Staining was also performed using Griffonia simplicifolia
isolectin B4 (GSL-I-B4, biotin-linked; Vector Laborato-
ries, Burlingame, Calif), as described previously,19,20 to
label vascular endothelial cells. A mouse antihuman -actin
monoclonal antibody (M0851, Dako, Glostrup, Denmark)
was used to label -actin in smooth muscle cells (-actin
SMC), as a means of assessing the density of small vessels.
Nuclei were counterstained with hematoxylin. Histologic
examination was performed in a blinded fashion. GSL-I-
B4-positive capillaries or -actin SMC–positive arterioles
were counted in six randomly selected fields from six dif-
ferent sections per muscle at original magnification 200.
Results are presented as the number of small vessels per
muscle fiber.
Statistical analysis. Analysis of variance was used for
intergroup comparisons. Friedman’s test was used for com-
parisons between the three groups. Results are reported asthe mean  SD. P  .05 was considered to indicate
statistical significance.
RESULTS
None of the rabbits died during the experiment. All
rabbits could hop normally, but their appetite and activity
Fig 1. Gene expression.A, Total RNAwas extracted from adduc-
tor muscles transfected with platelet-derived endothelial growth
factor/thymidine phosphorylase (PD-ECGF/TP), and real-time
polymerase chain reaction (PCR) was performed using a specific
primer for human PD-ECGF/TP. PCR for rabbit -actin was also
performed as a loading control. B, Immunoblot analysis of human
PD-ECGF/TP. *P 0.05. C, X-gal staining to detect LacZ gene
expression (arrow).seemed to be reduced in the LacZ and saline groups.
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occurred in three rabbits from the LacZ group, two from
the saline group, and one from the PD-ECGF/TP group.
There was a lower incidence of limb necrosis in the PD-
ECGF/TP group, but no significant differences were
noted between the groups (P  NS).
Transgene expression. Thirty days after gene trans-
fection, human PD-ECGF/TP mRNA was detected in six
of eight rabbits in the PD-ECGF/TP group, but not in the
other groups (Fig 1, A). Immunoblot analysis demon-
strated that expression of PD-ECGF/TP was higher in the
PD-ECGF/TP group than in the control groups (Fig 1, B).
In addition, X-gal staining demonstrated LacZ gene expres-
sion, which was mainly in the intermuscular space (Fig 1, C).
Calf blood pressure. Calf blood pressure did not
differ between the three groups before devascularization,
and the blood pressure was not measurable in the ischemic
limb immediately after surgery in any group (data not
shown). Ten days after femoral artery resection (immedi-
ately before gene transfection), there was still no difference
in calf blood pressure between the groups (PD-ECGF/TP,
0.04  0.04; LacZ, 0.00  0.00; saline, 0.50  0.05; P 
NS). At 20 days after treatment, the calf blood pressure was
significantly increased in all three groups, but it was higher
in the PD-ECGF/TP group (0.84  0.07) than in the
controls (LacZ, 0.55  0.04; saline, 0.50  0.04; PD-
ECGF/TP vs LacZ or saline, both P .01). This difference
became more marked by 30 days after gene transfection
(Fig 2).
Quantitative angiographic findings. Ten days after
induction of ischemia, no significant difference was noted
in the angiographic score among the three groups (PD-
ECGF/TP, 0.51  0.04; LacZ, 0.50  0.03; saline,
0.51  0.03). At 30 days after treatment, however, collat-
Fig 2. Calf blood pressure was measured before devascularization
surgery (day 0), before gene transfer (day 10 after surgery), 30 days
after surgery (20 days after gene transfer), and 40 days after surgery
(30 days after gene transfer). Data are shown as the ratio of the
ischemic to normal hindlimb. Complete resection of the left fem-
oral artery resulted in a similar decrease of the calf blood pressure
ratio in the three groups before initiation of therapy on day 10. Calf
blood pressure ratios on day 30 and day 40 were higher in the
platelet-derived endothelial growth factor/thymidine phosphory-
lase (PD-ECGF/TP) group than in the LacZ and saline groups.
The calf blood pressure ratio did not significantly differ between
the LacZ and saline groups. Data are reported as the mean  SD.
*P  0.01 vs LacZ and saline groups.eral arteries in the medial thigh were more extensive in thePD-ECGF/TP group than in the LacZ and saline groups
(Fig 3, A). Quantitative analysis confirmed that the angio-
graphic score was higher in the PD-ECGF/TP group than
in the controls (PD-ECGF/TP, 0.96  0.08; LacZ,
0.50  0.02; saline, 0.51  0.03; both P  .01) (Fig 3, B).
Histologic findings. The gastrocnemius-soleus mus-
cle complex was isolated from each rabbit and the wet
weight was measured. Data are presented as ratio of the
left to right muscles. There were no differences of the
wet weight ratio among the three groups (PD-ECGF,
0.98  0.033; LacZ, 0.96  0.03; and saline, 0.95 
0.04, P  NS).
Hematoxylin and eosin staining failed to demonstrate
any significant morphologic abnormalities in the three
groups. No edema, muscle fiber hypertrophy, or inflamma-
tory cell infiltration was noted in any of the groups, nor was
there necrosis of the adductor muscles (data not shown).
Immunohistochemical staining for biotin-labeled GSL-I-
B4, which specifically identifies endothelial cells, demon-
strated amarked increase of capillary density in the PD-ECGF
group. The capillary density (calculated as the number of
capillaries per muscle fiber) was higher in the PD-ECGF/TP
Fig 3. Angiographic findings. A, Representative image. B, An-
giographic score analysis. PD-ECGF/TP, Platelet-derived endo-
thelial growth factor/thymidine phosphorylase. Data are reported
as the mean SD. *P 0.01, PD-ECGF/TP vs LacZ and saline.group than in the LacZ or saline groups (Fig 4).
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riolar density in the PD-ECGF/TP group than in the LacZ
or saline groups (Fig 5). No differences of capillary or
arteriolar density were noted between the LacZ and saline
groups. The density of muscle fibers was similar between
the three groups (data not shown).
Staining for single-stranded DNA showed that the
density of apoptotic cells was lower in the PD-ECGF/TP
group than in the LacZ or saline groups, suggesting that
apoptosis may have been reduced in PD-ECGF/TP-
treated animals (Fig 6).
DISCUSSION
This study used a rabbit hindlimb ischemic model to
demonstrate that the intramuscular injection of a plasmid
vector encoding human PD-ECGF/TP can enhance the
angiogenic response to ischemia at the capillary and arte-
riolar level, leading to a significant increase of the regional
collateral circulation.
PD-ECGF first was isolated in 1987.21 Five years later,
it was shown to be identical to TP, a previously character-
ized intracellular enzyme.22 Considerable experimental ev-
idence supports a relationship between PD-ECGF/TP and
tumor angiogenesis.23,24 In our previous study, we found
that transfer of the PD-ECGF/TP gene in a plasmid vector
stimulated angiogenesis and arteriogenesis in ischemic
myocardium, inhibitedmyocardial apoptosis, decreased the
extent of myocardial infarction, and improved myocardial
blood flow and cardiac function.13 The present study ex-
tends our investigation of the angiogenic effects of PD-
Fig 4. Upper panels, Immunohistochemical staining of endo-
thelial cells in adductor muscle tissue using biotin-labeled GSL-
I-B4 (original magnification 200, bars  50 m). Graph, The
columns show the capillary density relative to muscle fiber num-
bers. Data are reported as the mean SD. PD-ECGF/TP, Platelet-
derived endothelial growth factor/thymidine phosphorylase. *P
.01, PD-ECGF vs LacZ and saline.ECGF/TP gene therapy to the peripheral vascular system.Therapeutic angiogenesis seeks to improve tissue per-
fusion by promoting the growth and proliferation of blood
vessels through the delivery of angiogenic cytokines such as
VEGF and FGF. Recently, Khurana et al25 demonstrated
that VEGF and FGF promoted (but could not initiate)
neointima formation after balloon-induced vascular injury
in rats or collar-induced carotid ischemia in rabbits. How-
ever, the Vascular Endothelial Growth Factor in Ischemia
for Vascular Angiogenesis (VIVA) trial, the only phase II
trial reported in this field, showed that treatment with
VEGF protein failed to increase exercise tolerance or im-
prove angina compared with placebo.26,27 The side effects
of VEGF and FGF also emphasize the need for examination
of other potential angiogenic factors.
The principal goal of angiogenic therapy is to develop
collateral vessels that can provide sufficient blood flow to
the pre-existing vascular network in ischemic tissue.28
Newly formed capillaries lack vascular SMCs (VSMCs) and
therefore have little or no effect on total vascular resistance.
In contrast, arteriogenesis involves the growth, develop-
ment, and remodeling of pre-existing vessels (mainly arte-
rioles) into larger collateral arteries of sufficient diameter to
be visualized by angiography that can serve as conduit
arteries and influence vascular resistance.28-30
Optimal development of the collateral circulation re-
quires delivery of an appropriate growth factor to its appro-
priate target. In the present study, regional injection of the
PD-ECGF/TP gene caused a marked increase of capillary
Fig 5. Arteriogenesis was analyzed by immunohistochemical stain-
ing for -actin smooth muscle cells, and the arteriolar density was
quantified.Upper panels, Representative staining (original magnifi-
cation 200, bars  50 m). Graph, The columns indicate the
arteriolar density relative to muscle fiber numbers. Data are reported
as the mean  SD. PD-ECGF/TP, Platelet-derived endothelial
growth factor/thymidine phosphorylase. *P  .01, PD-ECGF vs
LacZ and saline.and arteriolar density that paralleled the increase of calf
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TP-treated group and suggests that treatment of ischemic
limbs by PD-ECGF/TP gene transfer can promote collat-
eral vessel development. Similar effects were also identified in
our previous study of chronic ischemic canine myocardium.13
In the present study, real-time PCR confirmed the
expression of PD-ECGF/TPmRNA, and immunoblotting
also demonstrated increased expression of PD-ECGF/TP
protein at 30 days after gene injection, although the actual
amount was low. We have previously demonstrated a ther-
apeutic effect of PD-ECGF on early (2 weeks) myocardial
ischemia, and once a blood vessel network has developed, it
is permanent. Therefore, the functional improvement is
long-term, even if transgene expression decreases or be-
comes undetectable.
Abnormal regulation of the growth and motility of
VSMCs has been implicated as a mechanism of occlusive
vascular disease, so the effects of growth factors on VSMCs
need to be considered. In this respect, we recently observed
a potentially favorable effect of PD-ECGF/TP; that is, the
inhibition by of VSMC proliferation and migration both in
vitro and in vivo.31 Thus, PD-ECGF/TP could decrease
neointimal smooth muscle cell proliferation and thereby
reduce the neointimal volume in atherosclerotic vessels
to inhibit the progression of atherosclerosis. Of course,
VSMCs are necessary for vascular maturation and arterio-
genesis,32 which is the process by which capillaries acquire
a VSMC coat to become arterioles with the ability to
regulate blood flow.
VSMCs have a complex origin that may vary between
tissues.5 Generally, VSMCs are believed to differentiate
from mesenchymal cells, with potential precursors includ-
ing cells such as pericytes,19 stromal cells, myoepithelial
cells, and myofibroblasts. VSMCs can also differentiate
from endothelial cells or from bone marrow precursors and
Fig 6. Representative immunohistochemical staining for single-
stranded DNA in the saline group. Nuclei were counterstained with
hematoxylin. Arrows indicate apoptotic cells (original magnification
200).macrophages.5 Conversely, under pathologic conditionssuch as restenosis or atherosclerosis, SMCs often dediffer-
entiate to an embryonic phenotype, reverting from con-
tractile to synthetic.5
Based on our previous results obtained in a model of
chronic myocardial ischemia using PD-ECGF/TP, as well
as the data obtained from this study, we speculate that
PD-ECGF/TP not only promotes arteriogenesis but may
also inhibit VSMC proliferation and migration from the
media to the intima in injured vessels. The in vivo effect of
PD-ECGF/TP on VSMCs may depend on the cellular
phenotype. We are currently investigating the mechanisms
underlying the inhibitory effects of PD-ECGF/TP on
VSMCs.
This study had several limitations. One was that we did
not perform hematologic tests, and the second was the
limited value of angiographic examination. Although only
larger microvessels can be visualized by angiography, this
technique at least showed that the angiographic score
did not improve in controls, whereas increased arterio-
genesis in the PD-ECGF group led to an increase of
visible microvessels.
CONCLUSION
Plasmid vector-mediated gene transfer of PD-ECGF/TP
improved limb ischemia in rabbits by promoting angiogen-
esis and collateral vessel development. These findings sug-
gest that PD-ECGF/TP gene therapy for peripheral arte-
rial disease warrants further investigation.
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